GlassScriptPhysician profile
Schield M Wikas
NPI 1174544068
$8,774.63
in general payments reported to CMS, 2019-2025
29 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 75% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $504 · 2021: $678 · 2022: $990 · 2023: $1,145 · 2024: $2,463 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,214 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,213.77 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,008.55 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,431.54 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,382.74 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $708.46 | 2019-2025 | |
| Lilly USA, LLC | $367.71 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $353.81 | 2019-2025 | |
| Genzyme Corporation | $310.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $302.90 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $258.17 | 2022-2025 | Opzelura |
| Pfizer INC. | $253.11 | 2022-2025 | |
| Galderma Laboratories, L.P. | $249.54 | 2020-2025 | Nemluvio, Aklief |
| Ucb, INC. | $249.19 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $157.47 | 2024 | Vtama |
| Leo Pharma INC. | $133.55 | 2019-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.09 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $100.00 | 2020 | |
| Biofrontera INC. | $86.50 | 2025 | |
| Sanofi-Aventis U.S. LLC | $58.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.55 | 2022-2024 | Spevigo |
| Amgen INC. | $38.33 | 2023-2024 | Otezla |
| Organon LLC | $36.94 | 2025 | Vtama |
| Mallinckrodt Hospital Products INC. | $34.85 | 2024 | Acthar |
| Kyowa Kirin, INC. | $16.00 | 2023 | Poteligeo |
| Nabriva Therapeutics, Plc | $15.17 | 2021 | |
| Dermira, INC. | $15.12 | 2020 | |
| Kerecis Limited | $13.74 | 2021 | |
| Botanix Sb INC | $13.68 | 2025 | Sofdra |
| Mission Pharmacal Company | $12.21 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Schield Wikas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.